Evidence map›Paper›PMID 26976970›Full record

ArticleAnticancer research2016

Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance.

Jamie N Hadac, Devon D Miller, Ian C Grimes, Linda Clipson, Michael A Newton, William R Schelman, Richard B Halberg

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Anticancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Jamie N HadacDepartment of Oncology, K4/532 Clinical Science Center, Madison, WI, U.S.A.
Devon D MillerDepartment of Medicine, Division of Gastroenterology and Hepatology, K4/532 Clinical Science Center, Madison, WI, U.S.A.
Ian C GrimesDepartment of Medicine, Division of Gastroenterology and Hepatology, K4/532 Clinical Science Center, Madison, WI, U.S.A.
Linda ClipsonDepartment of Oncology, K4/532 Clinical Science Center, Madison, WI, U.S.A.
Michael A NewtonDepartments of Statistics and of Biostatistics and Medical Informatics, 1245a, K6/434 Medical Sciences Center, Madison, WI, U.S.A.
William R SchelmanDepartment of Medicine, Division of Hematology and Oncology, K4/532 Clinical Science Center, Madison, WI, U.S.A.
Richard B HalbergDepartment of Medicine, Division of Gastroenterology and Hepatology, K4/532 Clinical Science Center, Madison, WI, U.S.A. Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, U.S.A. rbhalberg@medicine.wisc.edu.
University of Wisconsin–Madison · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Training in Cancer Biology Training GrantT32CA009135 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SUGDEN, WILLIAM M. · 1985 to 2024
$10.4M
PHYSICIAN SCIENTIST TRAINING IN CANCER MEDICINET32CA009614 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MCNEEL, DOUGLAS G. · 1988 to 2014
$3.8M
Molecular Differences Predicting Tumor Progression in Colorectal Cancer (PQ #14)R21CA170876 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI HALBERG, RICHARD BROTT, KENNEDY, GREGORY DEAN · 2012 to 2013
$350k
NCI NIH HHS P30 CA014520NCI NIH HHS R21 CA170876NCI NIH HHS T32 CA009135NCI NIH HHS T32 CA009614
6 · The paper itself

Abstract

backgroundDespite receiving post-operative 5-fluorouracil (5-FU)-based chemotherapy, approximately 50% of patients with stage IIIC colon cancer experience recurrence. Currently, no molecular signature can predict response to 5-FU. MATERIALS AND

methodsMouse models of colon cancer have been developed and characterized. Individual tumors in these mice can be longitudinally monitored and assessed to identify differences between those that are responsive and those that are resistant to therapy. Gene expression was analyzed in serial biopsies that were collected before and after treatment with 5-FU. Colon tumors had heterogeneous responses to treatment with 5-FU. Microarray analysis of pre-treatment biopsies revealed that Hp1bp3, a gene encoding heterochromatin protein 1 binding protein 3, was differentially expressed between sensitive and resistant tumors.

conclusionUsing mouse models of human colorectal cancer, Hp1bp3 was identified as a candidate marker of intrinsic 5-FU resistance and may represent a potential biomarker for patient stratification or a target of clinical importance.

Indexed as

Drug Resistance, NeoplasmAnimalsBiomarkers, TumorColonic NeoplasmsDextran SulfateFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiceNuclear ProteinsOligonucleotide Array Sequence AnalysisBiomarkers, TumorDextran SulfateFluorouracilHP1BP3 protein, mouseNuclear Proteins5-fluorouracilchemotherapyColorectal cancerheterochromatin protein 1 binding protein 3intrinsic resistancemouse models

Identifiers

PMID26976970
PMCPMC4876978
OpenAlexW2340235976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.